The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

Thorir D. Bjornsson, John T. Callaghan(Eli Lilly (United States)), Heidi J. Einolf(Novartis (United States)), Volker Fischer(Novartis (United States)), Lawrence L. Gan(Millennium Engineering and Integration (United States)), Scott Grimm(Wilmington University), John Y. Kao, S. P. King, Gerald T. Miwa(Millennium Engineering and Integration (United States)), Lan Ni(Eli Lilly (United States)), Gondi Kumar(Amgen (United States)), James F. McLeod(Novartis (United States)), Scott R. Obach(Pfizer (United States)), Stanley Roberts(Abbott Fund), Amy L. Roe(Procter & Gamble (United States)), Anita Shah(Bayer (United States)), Fred Snikeris(Sanofi (United States)), John T. Sullivan(Amgen (United States)), Donald Tweedie(Boehringer Ingelheim (United States)), José M. Vega(United States Military Academy), John Walsh(Research Triangle Park Foundation), Steven Wrighton(Eli Lilly (United States))
The Journal of Clinical Pharmacology
May 1, 2003
Cited by 53

Abstract


Related Papers

No related papers found

Powered by citation graph analysis